{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T01:36:57Z","timestamp":1771724217587,"version":"3.50.1"},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Variant Transthyretin Amyloidosis (ATTRv) neuropathy is an adult-onset, autosomal dominant,\nlethal, multisystemic disease due to the deposition of mutated transthyretin (TTR) in various organs,\ncommonly involving the peripheral nerves and the heart. Circulating TTR tetramers are unstable\ndue to the presence of mutated TTR and dissociate into monomers, which misfold and form amyloid\nfibrils. Although there are more than 140 mutations in the TTR gene, the p.Val50Met mutation is by\nfar the commonest. In the typical, early-onset cases, it presents with a small sensory fibre and autonomic,\nlength-dependent, axonal neuropathy, while in late-onset cases, it presents with a lengthdependent\nsensorimotor axonal neuropathy involving all fibre sizes. Treatment is now available and\nincludes TTR stabilizers, TTR amyloid removal as well as gene silencing, while gene editing therapies\nare on the way. Its timely diagnosis is of paramount importance for a better prognosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x21666221108094736","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T06:08:31Z","timestamp":1668146911000},"page":"471-481","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis\n(ATTRv) Neuropathy"],"prefix":"10.2174","volume":"21","author":[{"given":"Efthimios","family":"Dardiotis","sequence":"first","affiliation":[{"name":"Laboratory of Neurogenetics, Department of Neurology, School of Health Sciences, Faculty of Medicine, University\nHospital of Larissa, Larissa, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Kyriakides","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Sciences, University of Nicosia Medical\nSchool, Nicosia, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"Plant\u00e9-Bordeneuve V.","year":"2011","unstructured":"Plant\u00e9-Bordeneuve V.; Said G.; Familial amyloid polyneuropathy. Lancet Neurol 2011,10(12),1086-1097","journal-title":"Lancet Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"12224","DOI":"10.1016\/S0021-9258(17)39013-0","volume":"260","author":"Tsuzuki T.","year":"1985","unstructured":"Tsuzuki T.; Mita S.; Maeda S.; Araki S.; Shimada K.; Structure of the human prealbumin gene. J Biol Chem 1985,260(22),12224-12227","journal-title":"J Biol Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","volume":"9","author":"Liz M.A.","year":"2020","unstructured":"Liz M.A.; Coelho T.; Bellotti V.; Fernandez-Arias M.I.; Mallaina P.; Obici L.; a narrative review of the role of transthyretin in health and disease. Neurol Ther 2020,9(2),395-402","journal-title":"Neurol Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.1007\/s00018-021-03899-3","volume":"78","author":"Magalh\u00e3es J.","year":"2021","unstructured":"Magalh\u00e3es J.; Eira J.; Liz M.A.; The role of transthyretin in cell biology: impact on human pathophysiology. Cell Mol Life Sci 2021,78(17-18),6105-6117","journal-title":"Cell Mol Life Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1749-6632.1984.tb13742.x","volume":"435","author":"Saraiva M.J.M.","year":"1984","unstructured":"Saraiva M.J.M.; Birken S.; Costa P.P.; Goodman D.S.; Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy. Ann N Y Acad Sci 1984,435,86-100","journal-title":"Ann N Y Acad Sci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/13506129.2018.1534731","volume":"25","author":"Andreou S.","year":"2018","unstructured":"Andreou S.; Panayiotou E.; Michailidou K.; Pirpa P.; Hadjisavvas A.; El Salloukh A.; Barnes D.; Antoniou A.; Agathangelou P.; Papastavrou K.; Christodoulou K.; Tanteles G.A.; Kyriakides T.; Epidemiology of ATTRV30M neuropathy in Cyprus and the modifier effect of complement C1q on the age of disease onset. Amyloid 2018,25(4),220-226","journal-title":"Amyloid"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"Schmidt H.H.","year":"2018","unstructured":"Schmidt H.H.; Waddington-Cruz M.; Botteman M.F.; Carter J.A.; Chopra A.S.; Hopps M.; Stewart M.; Fallet S.; Amass L.; Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 2018,57(5),829-837","journal-title":"Muscle Nerve"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/13506120802676948","volume":"16","author":"Dardiotis E.","year":"2009","unstructured":"Dardiotis E.; Koutsou P.; Papanicolaou E.Z.; Vonta I.; Kladi A.; Vassilopoulos D.; Hadjigeorgiou G.; Christodoulou K.; Kyriakides T.; Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid 2009,16(1),32-37","journal-title":"Amyloid"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.transproceed.2019.01.071","volume":"51","author":"Kavousanaki M.","year":"2019","unstructured":"Kavousanaki M.; Tzagournissakis, \u039c.; Zaganas, I.; Stylianou, K.G.; Patrianakos, A.P.; Tsilimbaris, M.K.; Mantaka, A.; Samonakis, D.N. Liver transplantation for familial amyloid polyneuropathy (Val30Met): Long-term follow-up prospective study in a nontransplant center. Transplant Proc 2019,51(2),429-432","journal-title":"Transplant Proc"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-9-29","volume":"9","author":"Rein\u00e9s J.","year":"2014","unstructured":"Rein\u00e9s J.; Vera T.; Mart\u00edn M.; Serra H.; Campins M.M.; Mill\u00e1n J.M.; Lezaun C.; Cruz M.; Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Ll\u00e0tzer Hospital descriptive study. Orphanet J Rare Dis 2014,9(1),29","journal-title":"Orphanet J Rare Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","volume":"59","author":"Koike H.","year":"2002","unstructured":"Koike H.; Misu K.; Ikeda S.; Ando Y.; Nakazato M.; Ando E.; Yamamoto M.; Hattori N.; Sobue G.; Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs. late-onset form. Arch Neurol 2002,59(11),1771-1776","journal-title":"Arch Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2018-0033","volume":"9","author":"Kristen A.V.","year":"2019","unstructured":"Kristen A.V.; Ajroud-Driss S.; Concei\u00e7\u00e3o I.; Gorevic P.; Kyriakides T.; Obici L.; Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegener Dis Manag 2019,9(1),5-23","journal-title":"Neurodegener Dis Manag"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10741-020-10062-w","volume":"26","author":"Bistola V.","year":"2021","unstructured":"Bistola V.; Parissis J.; Foukarakis E.; Valsamaki P.N.; Anastasakis A.; Koutsis G.; Efthimiadis G.; Kastritis E.; Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Fail Rev 2021,26(4),861-879","journal-title":"Heart Fail Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1096\/fj.11-189571","volume":"26","author":"Buxbaum J.N.","year":"2012","unstructured":"Buxbaum J.N.; Tagoe C.; Gallo G.; Walker J.R.; Kurian S.; Salomon D.R.; Why are some amyloidoses systemic? Does hepatic \u201cchaperoning at a distance\u201d prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J 2012,26(6),2283-2293","journal-title":"FASEB J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","volume":"121","author":"Sekijima Y.","year":"2005","unstructured":"Sekijima Y.; Wiseman R.L.; Matteson J.; Hammarstr\u00f6m P.; Miller S.R.; Sawkar A.R.; Balch W.E.; Kelly J.W.; The biological and chemical basis for tissue-selective amyloid disease. Cell 2005,121(1),73-85","journal-title":"Cell"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2009.05.018","volume":"284","author":"Dardiotis E.","year":"2009","unstructured":"Dardiotis E.; Koutsou P.; Zamba-Papanicolaou E.; Vonta I.; Hadjivassiliou M.; Hadjigeorgiou G.; Cariolou M.; Christodoulou K.; Kyriakides T.; Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. J Neurol Sci 2009,284(1-2),158-162","journal-title":"J Neurol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/acn3.748","volume":"6","author":"Dias A.","year":"2019","unstructured":"Dias A.; Santos D.; Coelho T.; Alves-Ferreira M.; Sequeiros J.; Alonso I.; Sousa A.; Lemos C.; C1 QA and C1 QC modify age\u2010at onset in familial amyloid polyneuropathy patients. Ann Clin Transl Neurol 2019,6(4),748-754","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175767","volume":"12","author":"Panayiotou E.","year":"2017","unstructured":"Panayiotou E.; Fella E.; Papacharalambous R.; Malas S.; Saraiva M.J.; Kyriakides T.; C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy. PLoS One 2017,12(4)","journal-title":"PLoS One"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"Andrade C.","year":"1952","unstructured":"Andrade C.; A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952,75(3),408-427","journal-title":"Brain"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","volume":"63","author":"Koike H.","year":"2004","unstructured":"Koike H.; Misu K.; Sugiura M.; Iijima M.; Mori K.; Yamamoto M.; Hattori N.; Mukai E.; Ando Y.; Ikeda S.; Sobue G.; Pathology of early- vs. late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 2004,63(1),129-138","journal-title":"Neurology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/13506129.2011.565524","volume":"18","author":"Koike H.","year":"2011","unstructured":"Koike H.; Hashimoto R.; Tomita M.; Kawagashira Y.; Iijima M.; Tanaka F.; Sobue G.; Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 2011,18(2),53-62","journal-title":"Amyloid"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.clinph.2016.02.013","volume":"127","author":"Castro J.","year":"2016","unstructured":"Castro J.; Miranda B.; Castro I.; de Carvalho M.; Concei\u00e7\u00e3o I.; The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy. Clin Neurophysiol 2016,127(5),2222-2227","journal-title":"Clin Neurophysiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10072-019-04176-9","volume":"41","author":"Dardiotis E.","year":"2020","unstructured":"Dardiotis E.; Andreou S.; Aloizou A.M.; Panayiotou E.; Siokas V.; Ioannou M.N.; Vounou E.; Christodoulou K.; Tanteles G.A.; Michaelides D.; Kyriakides T.; The frequency of central nervous system complications in the Cypriot cohort of ATTRV30M neuropathy transplanted patients. Neurol Sci 2020,41(5),1163-1170","journal-title":"Neurol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/13506129.2018.1554563","volume":"26","author":"Buxbaum J.N.","year":"2019","unstructured":"Buxbaum J.N.; Brannagan T.; Buades-Rein\u00e9s J.; Cisneros E.; Conceicao I.; Kyriakides T.; Merlini G.; Obici L.; Plante-Bordeneuve V.; Rousseau A.; Sekijima Y.; Imai A.; Waddington Cruz M.; Yamada M.; Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid 2019,26(1),10-14","journal-title":"Amyloid"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","volume":"87","author":"Sekijima Y.","year":"2016","unstructured":"Sekijima Y.; Yazaki M.; Oguchi K.; Ezawa N.; Yoshinaga T.; Yamada M.; Yahikozawa H.; Watanabe M.; Kametani F.; Ikeda S.; Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology 2016,87(8),773-781","journal-title":"Neurology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","volume":"86","author":"Maia L.F.","year":"2015","unstructured":"Maia L.F.; Magalh\u00e3es R.; Freitas J.; Taipa R.; Pires M.M.; Os\u00f3rio H.; Dias D.; Pessegueiro H.; Correia M.; Coelho T.; CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry 2015,86(2),159-167","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1212\/WNL.0000000000012965","volume":"97","author":"Sousa L.","year":"2021","unstructured":"Sousa L.; Coelho T.; Taipa R.; CNS Involvement in hereditary transthyretin amyloidosis. Neurology 2021,97(24),1111-1119","journal-title":"Neurology"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"Luigetti M.","year":"2020","unstructured":"Luigetti M.; Romano A.; Di Paolantonio A.; Bisogni G.; Sabatelli M.; Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: Current perspectives on improving patient care. Ther Clin Risk Manag 2020,16,109-123","journal-title":"Ther Clin Risk Manag"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2215\/CJN.08720811","volume":"7","author":"Lobato L.","year":"2012","unstructured":"Lobato L.; Rocha A.; Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol 2012,7(8),1337-1346","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"Adams D.","year":"2016","unstructured":"Adams D.; Suhr O.B.; Hund E.; Obici L.; Tournev I.; Campistol J.M.; Slama M.S.; Hazenberg B.P.; Coelho T.; First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016,29(Suppl. 1),S14-S26","journal-title":"Curr Opin Neurol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","volume":"121","author":"Pilebro B.","year":"2016","unstructured":"Pilebro B.; Suhr O.B.; N\u00e4slund U.; Westermark P.; Lindqvist P.; Sundstr\u00f6m T.; 99m Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci 2016,121(1),17-24","journal-title":"Ups J Med Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"Holmgren G.","year":"1991","unstructured":"Holmgren G.; Steen L.; Ekstedt J.; Groth C.G.; Ericzon B.G.; Eriksson S.; Andersen O.; Karlberg I.; Nord\u00e9n G.; Nakazato M.; Hawkins P.; Richardson S.; Pepys M.; Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991,40(3),242-246","journal-title":"Clin Genet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"Ericzon B.G.","year":"2015","unstructured":"Ericzon B.G.; Wilczek H.E.; Larsson M.; Wijayatunga P.; Stangou A.; Pena J.R.; Furtado E.; Barroso E.; Daniel J.; Samuel D.; Adam R.; Karam V.; Poterucha J.; Lewis D.; Ferraz-Neto B.H.; Cruz M.W.; Munar-Ques M.; Fabregat J.; Ikeda S.; Ando Y.; Heaton N.; Otto G.; Suhr O.; Liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2015,99(9),1847-1854","journal-title":"Transplantation"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/13506120701614032","volume":"14","author":"Liepnieks J.J.","year":"2007","unstructured":"Liepnieks J.J.; Benson M.D.; Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid 2007,14(4),277-282","journal-title":"Amyloid"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/13506129.2014.989318","volume":"22","author":"Beir\u00e3o J.M.","year":"2015","unstructured":"Beir\u00e3o J.M.; Malheiro J.; Lemos C.; Matos E.; Beir\u00e3o I.; Pinho-Costa P.; Torres P.; Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid 2015,22(1),31-35","journal-title":"Amyloid"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"Bulawa C.E.","year":"2012","unstructured":"Bulawa C.E.; Connelly S.; DeVit M.; Wang L.; Weigel C.; Fleming J.A.; Packman J.; Powers E.T.; Wiseman R.L.; Foss T.R.; Wilson I.A.; Kelly J.W.; Labaudini\u00e8re R.; Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012,109(24),9629-9634","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1042\/BJ20040011","volume":"381","author":"Almeida M.R.","year":"2004","unstructured":"Almeida M.R.; Macedo B.; Cardoso I.; Alves I.; Valencia G.; Arsequell G.; Planas A.; Saraiva M.J.; Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J 2004,381(2),351-356","journal-title":"Biochem J"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","volume":"56","author":"Tojo K.","year":"2006","unstructured":"Tojo K.; Sekijima Y.; Kelly J.W.; Ikeda S.; Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res 2006,56(4),441-449","journal-title":"Neurosci Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"Coelho T.","year":"2012","unstructured":"Coelho T.; Maia L.F.; Martins da Silva A.; Waddington Cruz M.; Plant\u00e9-Bordeneuve V.; Lozeron P.; Suhr O.B.; Campistol J.M.; Concei\u00e7\u00e3o I.M.; Schmidt H.H.J.; Trigo P.; Kelly J.W.; Labaudini\u00e8re R.; Chan J.; Packman J.; Wilson A.; Grogan D.R.; Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 2012,79(8),785-792","journal-title":"Neurology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"Berk J.L.","year":"2013","unstructured":"Berk J.L.; Suhr O.B.; Obici L.; Sekijima Y.; Zeldenrust S.R.; Yamashita T.; Heneghan M.A.; Gorevic P.D.; Litchy W.J.; Wiesman J.F.; Nordh E.; Corato M.; Lozza A.; Cortese A.; Robinson-Papp J.; Colton T.; Rybin D.V.; Bisbee A.B.; Ando Y.; Ikeda S.; Seldin D.C.; Merlini G.; Skinner M.; Kelly J.W.; Dyck P.J.; Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013,310(24),2658-2667","journal-title":"JAMA"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/ene.13510","volume":"25","author":"Gundapaneni B.K.","year":"2018","unstructured":"Gundapaneni B.K.; Sultan M.B.; Keohane D.J.; Schwartz J.H.; Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol 2018,25(3),464-468","journal-title":"Eur J Neurol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"Plant\u00e9-Bordeneuve V.","year":"2017","unstructured":"Plant\u00e9-Bordeneuve V.; Gorram F.; Salhi H.; Nordine T.; Ayache S.S.; Le Corvoisier P.; Azoulay D.; Feray C.; Damy T.; Lefaucheur J.P.; Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol 2017,264(2),268-276","journal-title":"J Neurol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"Barroso F.A.","year":"2017","unstructured":"Barroso F.A.; Judge D.P.; Ebede B.; Li H.; Stewart M.; Amass L.; Sultan M.B.; Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 2017,24(3),194-204","journal-title":"Amyloid"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10286-019-00625-9","volume":"29","author":"Cruz M.W.","year":"2019","unstructured":"Cruz M.W.; Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. Clin Auton Res 2019,29(S1)(Suppl. 1),19-24","journal-title":"Clin Auton Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"Maurer M.S.","year":"2018","unstructured":"Maurer M.S.; Schwartz J.H.; Gundapaneni B.; Elliott P.M.; Merlini G.; Waddington-Cruz M.; Kristen A.V.; Grogan M.; Witteles R.; Damy T.; Drachman B.M.; Shah S.J.; Hanna M.; Judge D.P.; Barsdorf A.I.; Huber P.; Patterson T.A.; Riley S.; Schumacher J.; Stewart M.; Sultan M.B.; Rapezzi C.; Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018,379(11),1007-1016","journal-title":"N Engl J Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"Damy T.","year":"2021","unstructured":"Damy T.; Garcia-Pavia P.; Hanna M.; Judge D.P.; Merlini G.; Gundapaneni B.; Patterson T.A.; Riley S.; Schwartz J.H.; Sultan M.B.; Witteles R.; Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR\u2010ACT) and long\u2010term extension study. Eur J Heart Fail 2021,23(2),277-285","journal-title":"Eur J Heart Fail"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"81-82","DOI":"10.1080\/13506129.2016.1277697","volume":"24","author":"Rocha A.","year":"2017","unstructured":"Rocha A.; Silva A.; Cardoso M.; Beirao I.; Alves C.; Teles P.; Coelho T.; Lobato L.; Transthyretin (ATTR) amyloidosis nephropathy: Lessons from a TTR stabilizer molecule. Amyloid 2017,24(sup1),81-82"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"67-68","DOI":"10.1080\/13506129.2019.1583186","volume":"26","author":"Ferrer-Nadal A.","year":"2019","unstructured":"Ferrer-Nadal A.; Ripoll T.; Uson M.; Figuerola A.; Andreu H.; Losada I.; Gonzalez J.; Cisneros-Barroso E.; Buades J.;  Significant reduction in proteinuria after treatment with tafamidis Amyloid 2019,26(sup1),67-68","journal-title":"Significant reduction in proteinuria after treatment with tafamidis Amyloid"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/13506129.2018.1479249","volume":"25","author":"Monteiro C.","year":"2018","unstructured":"Monteiro C.; Martins da Silva A.; Ferreira N.; Mesgarzadeh J.; Novais M.; Coelho T.; Kelly J.W.; Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid 2018,25(2),120-128","journal-title":"Amyloid"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/13506129.2014.997872","volume":"22","author":"Sekijima Y.","year":"2015","unstructured":"Sekijima Y.; Tojo K.; Morita H.; Koyama J.; Ikeda S.; Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 2015,22(2),79-83","journal-title":"Amyloid"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","volume":"27","author":"Ibrahim M.","year":"2022","unstructured":"Ibrahim M.; Saint Croix G.R.; Lacy S.; Fattouh M.; Barillas-Lara M.I.; Behrooz L.; Mechanic O.; The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev 2022,27(2),517-524","journal-title":"Heart Fail Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cpdd.700","volume":"9","author":"Fox J.C.","year":"2020","unstructured":"Fox J.C.; Hellawell J.L.; Rao S.; O\u2019Reilly T.; Lumpkin R.; Jernelius J.; Gretler D.; Sinha U.; First\u2010in\u2010human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: A phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers. Clin Pharmacol Drug Dev 2020,9(1),115-129","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"Judge D.P.","year":"2019","unstructured":"Judge D.P.; Heitner S.B.; Falk R.H.; Maurer M.S.; Shah S.J.; Witteles R.M.; Grogan M.; Selby V.N.; Jacoby D.; Hanna M.; Nativi-Nicolau J.; Patel J.; Rao S.; Sinha U.; Turtle C.W.; Fox J.C.; Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2019,74(3),285-295","journal-title":"J Am Coll Cardiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/febs.15339","volume":"288","author":"Pinheiro F.","year":"2021","unstructured":"Pinheiro F.; Varej\u00e3o N.; Esperante S.; Santos J.; Vel\u00e1zquez-Campoy A.; Reverter D.; Pallar\u00e8s I.; Ventura S.; Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. FEBS J 2021,288(1),310-324","journal-title":"FEBS J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1080\/13506129.2019.1597702","volume":"26","author":"Gamez J.","year":"2019","unstructured":"Gamez J.; Salvad\u00f3 M.; Reig N.; Su\u00f1\u00e9 P.; Casasnovas C.; Rojas-Garcia R.; Insa R.; Transthyretin stabilization activity of the catechol- O -methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid 2019,26(2),74-84","journal-title":"Amyloid"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1479-5876-8-74","volume":"8","author":"Cardoso I.","year":"2010","unstructured":"Cardoso I.; Martins D.; Ribeiro T.; Merlini G.; Saraiva M.J.; Synergy of combined Doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010,8(1),74","journal-title":"J Transl Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"34-36","DOI":"10.3109\/13506129.2012.678508","volume":"19","author":"Obici L.","year":"2012","unstructured":"Obici L.; Cortese A.; Lozza A.; Lucchetti J.; Gobbi M.; Palladini G.; Perlini S.; Saraiva M.J.; Merlini G.;  Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study Amyloid 2012,19(sup1Suppl. 1),34-36","journal-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study Amyloid"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"Richards D.B.","year":"2015","unstructured":"Richards D.B.; Cookson L.M.; Berges A.C.; Barton S.V.; Lane T.; Ritter J.M.; Fontana M.; Moon J.C.; Pinzani M.; Gillmore J.D.; Hawkins P.N.; Pepys M.B.; Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 2015,373(12),1106-1114","journal-title":"N Engl J Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"Adams D.","year":"2018","unstructured":"Adams D.; Gonzalez-Duarte A.; O\u2019Riordan W.D.; Yang C.C.; Ueda M.; Kristen A.V.; Tournev I.; Schmidt H.H.; Coelho T.; Berk J.L.; Lin K.P.; Vita G.; Attarian S.; Plant\u00e9-Bordeneuve V.; Mezei M.M.; Campistol J.M.; Buades J.; Brannagan T.H.; Kim B.J.; Oh J.; Parman Y.; Sekijima Y.; Hawkins P.N.; Solomon S.D.; Polydefkis M.; Dyck P.J.; Gandhi P.J.; Goyal S.; Chen J.; Strahs A.L.; Nochur S.V.; Sweetser M.T.; Garg P.P.; Vaishnaw A.K.; Gollob J.A.; Suhr O.B.; Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018,379(1),11-21","journal-title":"N Engl J Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"Benson M.D.","year":"2018","unstructured":"Benson M.D.; Waddington-Cruz M.; Berk J.L.; Polydefkis M.; Dyck P.J.; Wang A.K.; Plant\u00e9-Bordeneuve V.; Barroso F.A.; Merlini G.; Obici L.; Scheinberg M.; Brannagan T.H.; Litchy W.J.; Whelan C.; Drachman B.M.; Adams D.; Heitner S.B.; Concei\u00e7\u00e3o I.; Schmidt H.H.; Vita G.; Campistol J.M.; Gamez J.; Gorevic P.D.; Gane E.; Shah A.M.; Solomon S.D.; Monia B.P.; Hughes S.G.; Kwoh T.J.; McEvoy B.W.; Jung S.W.; Baker B.F.; Ackermann E.J.; Gertz M.A.; Coelho T.; Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018,379(1),22-31","journal-title":"N Engl J Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1208760","volume":"369","author":"Coelho T.","year":"2013","unstructured":"Coelho T.; Adams D.; Silva A.; Lozeron P.; Hawkins P.N.; Mant T.; Perez J.; Chiesa J.; Warrington S.; Tranter E.; Munisamy M.; Falzone R.; Harrop J.; Cehelsky J.; Bettencourt B.R.; Geissler M.; Butler J.S.; Sehgal A.; Meyers R.E.; Chen Q.; Borland T.; Hutabarat R.M.; Clausen V.A.; Alvarez R.; Fitzgerald K.; Gamba-Vitalo C.; Nochur S.V.; Vaishnaw A.K.; Sah D.W.Y.; Gollob J.A.; Suhr O.B.; Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013,369(9),819-829","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","volume":"10","author":"Suhr O.B.","year":"2015","unstructured":"Suhr O.B.; Coelho T.; Buades J.; Pouget J.; Conceicao I.; Berk J.; Schmidt H.; Waddington-Cruz M.; Campistol J.M.; Bettencourt B.R.; Vaishnaw A.; Gollob J.; Adams D.; Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis 2015,10(1),109","journal-title":"Orphanet J Rare Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","volume":"23","author":"Butler J.S.","year":"2016","unstructured":"Butler J.S.; Chan A.; Costelha S.; Fishman S.; Willoughby J.L.S.; Borland T.D.; Milstein S.; Foster D.J.; Gon\u00e7alves P.; Chen Q.; Qin J.; Bettencourt B.R.; Sah D.W.; Alvarez R.; Rajeev K.G.; Manoharan M.; Fitzgerald K.; Meyers R.E.; Nochur S.V.; Saraiva M.J.; Zimmermann T.S.; Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid 2016,23(2),109-118","journal-title":"Amyloid"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","volume":"20","author":"Adams D.","year":"2021","unstructured":"Adams D.; Polydefkis M.; Gonz\u00e1lez-Duarte A.; Wixner J.; Kristen A.V.; Schmidt H.H.; Berk J.L.; Losada L\u00f3pez I.A.; Dispenzieri A.; Quan D.; Concei\u00e7\u00e3o I.M.; Slama M.S.; Gillmore J.D.; Kyriakides T.; Ajroud-Driss S.; Waddington-Cruz M.; Mezei M.M.; Plant\u00e9-Bordeneuve V.; Attarian S.; Mauricio E.; Brannagan T.H.; Ueda M.; Aldinc E.; Wang J.J.; White M.T.; Vest J.; Berber E.; Sweetser M.T.; Coelho T.; Vita G.; Rizzo V.; Russo M.; Mazzeo A.; Gentile L.; Berk J.L.; Brueckner C.; Lazzari V.; Wiesman J.; DeLong D.; Victory J.; Dalton J.; May J.; Gilmore C.; Attarian S.; Diallo S.; Delmont E.; Pouget J.; Verschueren A.; Grapperon A-M.; Campana-Salort E.; Concei\u00e7\u00e3o I.M.; Lopes A.; Lamas F.; Neves C.; Castro J.; Pereira P.; Castro I.; Franco A.; Santos M.O.; de Azevedo Coutinho C.; Falcao de Campos C.; Coelho T.; Hip\u00f3lito Reis A.; Correia N.; Perez J.M.; Martins da Silva A.; Alves C.; Cardoso M.; Valdrez K.; Monte J.R.; Pessoa B.; Guimaraes N.; Freitas M.; Ramalho J.; Ferreira N.; Kuzume D.; Tard C.; Waucquier N.; Rougeaux I.; Brice S.; Kasprzyk E.; Elrezzi E.; Meguig S.; Hachulla E.; Gauvain C.; Migaud-Chervy M-C.; Deplanque D.; Jozefowicz E.; Lebellec L.; Adams D.; Balaya-Gouraya L.; Jehan Lacour N.; Bournane H.; Martin N.; Elabed M.; Sacko N.; Boubrit Y.; Gaouar A.; Rakotondratafika F.; Th\u00e9audin-Saliou M.; Cauquil-Michon C.; Labeyrie C.; Not A.; Al-Salameh A.; Lecoq A-L.; Stephant M.; Echaniz-Laguna A.; Becquemont L.; Beaudonnet G.; Algalarrondo V.; Eliahou L.; Slama M.S.; Rousseau A.; Signate A.; Berthelot E.; Inamo J.; Plant\u00e9-Bordeneuve V.; Vervoitte L.; Focseneanu C.; Gendre T.; Arrouasse R.; Ayache S.S.; Ernande L.; Le Corvoisier P.; Salhi H.; Choumert A.; Ehinger V.; Ruiz J.; Charlin C.; Megelin T.; Brannagan T.H.; Fayerman R.; Kim A.; Paras A.; Gonzalez L.J.; Tsang S.; Wajnsztajn F.; Shije J.; Ulane C.; Kleyman I.; Weimer L.; Cioroiu C.; Lambrianides S.; Abu-Manneh R.; Zamba-Papanicolaou E.; Agathangelou P.; Leonidou E.; Tada S.; Fujita A.; Nagai M.; Ando R.; Hosokawa Y.; Yamanishi Y.; Overcash J.S.; Giardino E.; Boyer L.; Dang L.; Le A.; Nguyen T.; Giang L.; Sellers P.; Tran L.; Truong N.; Vinas M.; Hrkman N.; Miller S.; Nguyen D.; Smith A.; Pu H.; Li S.; Vuong T.; Dioso H.; Green S.; Lee K.; Chu H.; Waters M.; Coskun D.J.; Zepeda K.A.; O\u2019Riordan W.; Obici L.; Cortese A.; Lozza A.; Merlini G.; Rosti V.; Sabatelli M.; Bisogni G.; Bernardo D.; Luigetti M.; Di Paolantonio A.; Guglielmino V.; Bisogni G.; Romano A.; Nienhuis H.; Bulthuis-Kuiper J.; Kristen A.V.; Gerk O.; Ulbricht H.; Taylor L.; Meyle E.; Kleinschmidt N.; Meyrath D.; Noe-Schwenn S.; Meng U.; Bauer R.; aus dem Siepen F.; Hein S.; Takahashi T.; Oshita T.; Koujin Y.; Neshige S.; Nezu T.; Segawa A.; Ueno H.; Morino H.; Campistol J.M.; Rodas Marin L.M.; Blasco P.J.M.; D\u00e1vila L.G.; Palacios M.; Pytel Cordoba V.; Guerrero S.A.; Horga A.; Garc\u00eda F.J.; Perez de Isla L.; Marques J\u00fanior W.; Moscardini M.; Litcanov D.C.; Viera Lima A.F.; Rodrigues L.; Marques C.B.; Moreira C.L.; Daccach M.V.; Munoz B.F.; Gragera Mart\u00ednez \u00c1.; Borrachero C.; Losada L.I.A.; Cisneros Barroso E.; Rodr\u00edguez R.A.; Sanz M.; Rigo Oliver E.; Gonz\u00e1lez Moreno J.; Gamez Martinez J.M.; Descals C.; Uson M.; Jose Vega F.; Figuerola A.; Montala C.; Waddington-Cruz M.; Dias da Silva M.; Gervais de Santa Rosa R.; Pinto L.F.; Pinto M.V.; Cardoso Berensztejn A.; Barroso F.; Lautre A.; Orellana L.G.; Gonz\u00e1lez-Duarte Brise\u00f1o M.A.; C\u00e1rdenas-Soto K.; Jim\u00e9nez L\u00f3pez B.P.; P\u00e9rez-Casta\u00f1eda S.L.; Cant\u00fa B.C.G.; Rivera de la Parra D.; Hernandez Reyes J.P.; del Mar Saniger Alba M.; Criollo Mora E.; Parman Y.; Rezzan K.J.; Sahin E.; Serbest N.G.; Durmus H.; Cakar A.; Tugal Tutkun N.I.; Karamursel S.; Elitok A.; Sirin Inan N.G.; Altinkurt E.; Polydefkis M.; Ye J.; Allen A.C.; Chaudhry V.; Jarrett R.; Bressler N.; Burks K.L.; Liu Q.; Khoshnoodi M.; Judge D.P.; Vista G.; Shah S.M.; Hamaguchi H.; Oda J.; Fukase E.; Taniguchi I.; Oda T.; Endo H.; Shimomura M.; Katanazaka K.; Koto S.; Nakano T.; Scheid C.; Zueiter A.; Pester L.; Walter D.; \u00d6zdemir B.; Frenzel L.F.; Holtick U.; Oh J.; Kim H.J.; Shin H.J.; Choi K.; Yamashita T.; Ueda M.; Masuda T.; Misumi Y.; Ueda A.; Nakahara K.; Yorita A.; Tsuruhisa S.; Taniwaki T.; Harada M.; Moritaka T.; Sakurada N.; Mauricio E.A.; Baskin A.; Dimberg E.; Dispenzieri A.; Fonder A.; Hobbs M.; Russell S.J.; Dyck P.; Gonsalves W.; Leung N.; Witzig T.E.; Zeldenrust S.R.; Hwa L.; Kapoor P.; Kumar S.K.; Lin Y.; Lust J.A.; Rajkumar V.S.; Dingli D.; Gertz M.A.; Go R.; Hayman S.R.; Dalia S.; Carrillo E.; Gorevic P.; Mason G.; Chao C-C.; Lee M-J.; Su J-J.; Hsieh S-T.; Tsai L-K.; Yeh S-J.; Yang C-C.; Ajroud-Driss S.A-D.; Casey P.; Joslin B.C.; Freimer M.; Sankey A.; Kenepp A.; Heintzman S.; LoRusso S.; Hokezu Y.; Kim B-J.; Kim J.H.; Lee G.Y.; Cho E.B.; Jeon E-S.; Min J-H.; Seok J.M.; Lee H.L.; Park J.H.; Sekijima Y.; Miyazawa C.; Kato N.; Kishida D.; Hineno A.; Kodaira M.; Yoshinaga T.; Miyahara T.; Imai A.; Matsumoto K.; Lin K-P.; Lee Y-C.; Wixner J.; Falk M.; Pilebro B.; Suhr O.; Lindqvist P.; Soderberg K.; Pedrosa-Domell\u00f6f F.; Anan I.; Nordh E.; Tournev I.; Zhelyazkova-Glaveeva S.; Cherneva Z.; Sarafov S.; Chamova T.; Cherninkova-Gopina S.; Schmidt H.H.; Friebel F.; Zibert A.; Mihailovic N.; Schubert F.; Vorona E.; Lahme L.; Huesing-Kabar A.; Schilling M.; Kabar I.; Gillmore J.D.; Martinez-Naharro A.; Chacko L.; Cohen O.; Law S.; Rezk T.; Lachmann H.J.; Quan D.; Blume B.; Dixon S.; Low S.C.; Chan S.L.; Lim H.E.L.; Goh K.J.; Mezei M.M.; Kraus D.; Jack K.; Wade N.K.; Lopate G.; Zwijack B.; Florence J.; Sommerville R.B.; Stewart G.; Ryder J.; Mekhael L.; Taylor M.; Suan D.; Wells K.; Stone P.; Wells K.; Itoya A.; Owusu-Sekyere M.; Thai D.; Chahine I.; Pedrosa S.; Do T.H.T.; Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol 2021,20(1),49-59","journal-title":"Lancet Neurol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"Solomon S.D.","year":"2019","unstructured":"Solomon S.D.; Adams D.; Kristen A.; Grogan M.; Gonz\u00e1lez-Duarte A.; Maurer M.S.; Merlini G.; Damy T.; Slama M.S.; Brannagan T.H.; Dispenzieri A.; Berk J.L.; Shah A.M.; Garg P.; Vaishnaw A.; Karsten V.; Chen J.; Gollob J.; Vest J.; Suhr O.; Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019,139(4),431-443","journal-title":"Circulation"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1007\/s00415-022-10978-3","volume":"269","author":"Bulinski C.","year":"2022","unstructured":"Bulinski C.; Discher T.; Rutsatz W.; Assmus B.; Kr\u00e4mer H.H.; Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation. J Neurol 2022,269(7),3912-3914","journal-title":"J Neurol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/ajt.17009","volume":"22","author":"Schmidt H.H.","year":"2022","unstructured":"Schmidt H.H.; Wixner J.; Plant\u00e9-Bordeneuve V.; Mu\u00f1oz-Beamud F.; Llad\u00f3 L.; Gillmore J.D.; Mazzeo A.; Li X.; Arum S.; Jay P.Y.; Adams D.; Langestroer C.; Huesing-Kabar A.; Schilling M.; Kabar I.; Backlund R.; Anan I.; Nordh E.; Uneus E.; Pilebro B.; Englund U.; Coelho T.; Novais M.; Perez J.; Martins da Silva A.; Pesseguerio M.H.; Ramalho J.; Monte R.; Alves C.; Cardaso I.; Guimaraes N.; Gentile L.; Russo M.; Di Bella G.; Gaouar A.; Cauquil-Michon C.; Kounis I.; Echaniz-Laguna A.; St\u00e9phant M.; Rakotondratafika F.; Boubrit Y.; Labeyrie C.; Focsenaunu C.; Le Corvoisier P.; Ayache S.S.; Gendre T.; Vervoitte L.; Arrouasse R.; Gragera M.A.; Borrachero C.; Manovel A.; Diaz Rodriguez E.; Guti\u00e9rrez G.M.; Fabra J.E.; Valentina V\u00e9lez Santamar\u00eda P.; Mart\u00ednez Vilar Y.; Cachero A.; Rannigan L.; Fontana M.; Orrell R.; Louth S.; Chacko L.; Varughese S.; Throburn D.; Cohen O.; Law S.; Smit A.; Strehina S.; Patisiran treatment in patients with hereditary transthyretin\u2010mediated amyloidosis with polyneuropathy after liver transplantation. Am J Transplant 2022,22(6),1646-1657","journal-title":"Am J Transplant"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14656566.2018.1554648","volume":"20","author":"Plant\u00e9-Bordeneuve V.","year":"2019","unstructured":"Plant\u00e9-Bordeneuve V.; Lin H.; Gollob J.; Agarwal S.; Betts M.; Fahrbach K.; Chitnis M.; Polydefkis M.; An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. Expert Opin Pharmacother 2019,20(4),473-481","journal-title":"Expert Opin Pharmacother"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13506129.2016.1256282","volume":"23","author":"Gon\u00e7alves P.","year":"2016","unstructured":"Gon\u00e7alves P.; Martins H.; Costelha S.; Maia L.F.; Saraiva M.J.; Efficiency of silencing RNA for removal of transthyretin V30M in a TTR leptomeningeal animal model. Amyloid 2016,23(4),249-253","journal-title":"Amyloid"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/cpt.1974","volume":"109","author":"Habtemariam B.A.","year":"2021","unstructured":"Habtemariam B.A.; Karsten V.; Attarwala H.; Goel V.; Melch M.; Clausen V.A.; Garg P.; Vaishnaw A.K.; Sweetser M.T.; Robbie G.J.; Vest J.; Single\u2010dose pharmacokinetics and pharmacodynamics of transthyretin targeting N\u2010acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther 2021,109(2),372-382","journal-title":"Clin Pharmacol Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/ene.14285","volume":"27","author":"Brannagan T.H.","year":"2020","unstructured":"Brannagan T.H.; Wang A.K.; Coelho T.; Waddington Cruz M.; Polydefkis M.J.; Dyck P.J.; Plante-Bordeneuve V.; Berk J.L.; Barroso F.; Merlini G.; Concei\u00e7\u00e3o I.; Hughes S.G.; Kwoh J.; Jung S.W.; Guthrie S.; Pollock M.; Benson M.D.; Gertz M.; Drachman B.; Gorevic P.; Heitner S.; Scheinberg M.; Schmidt H.; Whelan C.; Adams D.; Campistol P.J.M.; Gamez J.; Gane E.; Kristen A.; Obici L.; Salvi F.; Souza Bulle Oliveira A.; Vita G.; Early data on long\u2010term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2\u2010year update from the open\u2010label extension of the NEURO\u2010TTR trial. Eur J Neurol 2020,27(8),1374-1381","journal-title":"Eur J Neurol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/nmt-2018-0037","volume":"9","author":"Benson M.D.","year":"2019","unstructured":"Benson M.D.; Dasgupta N.R.; Monia B.P.; Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. Neurodegener Dis Manag 2019,9(1),25-30","journal-title":"Neurodegener Dis Manag"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/mus.20503","volume":"33","author":"Benson M.D.","year":"2006","unstructured":"Benson M.D.; Kluve-Beckerman B.; Zeldenrust S.R.; Siesky A.M.; Bodenmiller D.M.; Showalter A.D.; Sloop K.W.; Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 2006,33(5),609-618","journal-title":"Muscle Nerve"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","volume":"10","author":"Coelho T.","year":"2021","unstructured":"Coelho T.; Ando Y.; Benson M.D.; Berk J.L.; Waddington-Cruz M.; Dyck P.J.; Gillmore J.D.; Khella S.L.; Litchy W.J.; Obici L.; Monteiro C.; Tai L.J.; Viney N.J.; Buchele G.; Brambatti M.; Jung S.W.; St L.; O\u2019Dea, L.; Tsimikas, S.; Schneider, E.; Geary, R.S.; Monia, B.P.; Gertz, M. Design and rationale of the global phase 3 NEURO-Ttransform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther 2021,10(1),375-389","journal-title":"Neurol Ther"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"Dasgupta N.R.","year":"2020","unstructured":"Dasgupta N.R.; Rissing S.M.; Smith J.; Jung J.; Benson M.D.; Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 2020,27(1),52-58","journal-title":"Amyloid"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/13506129.2010.483121","volume":"17","author":"Benson M.D.","year":"2010","unstructured":"Benson M.D.; Smith R.A.; Hung G.; Kluve-Beckerman B.; Showalter A.D.; Sloop K.W.; Monia B.P.; Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment. Amyloid 2010,17(2),43-49","journal-title":"Amyloid"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/13506129.2021.1975673","volume":"28","author":"Marques J.H.","year":"2021","unstructured":"Marques J.H.; Coelho J.; Men\u00e9res M.J.; Beir\u00e3o J.M.; Progressive vitreous deposits during treatment with inotersen for hereditary ATTR amyloidosis. Amyloid 2021,28(4),275-276","journal-title":"Amyloid"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/13506129.2020.1784134","volume":"27","author":"Moshe-Lilie O.","year":"2020","unstructured":"Moshe-Lilie O.; Dimitrova D.; Heitner S.B.; Brannagan T.H.; Zivkovic S.; Hanna M.; Masri A.; Polydefkis M.; Berk J.L.; Gertz M.A.; Karam C.; TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients. Amyloid 2020,27(4),250-253","journal-title":"Amyloid"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"Finn J.D.","year":"2018","unstructured":"Finn J.D.; Smith A.R.; Patel M.C.; Shaw L.; Youniss M.R.; van Heteren J.; Dirstine T.; Ciullo C.; Lescarbeau R.; Seitzer J.; Shah R.R.; Shah A.; Ling D.; Growe J.; Pink M.; Rohde E.; Wood K.M.; Salomon W.E.; Harrington W.F.; Dombrowski C.; Strapps W.R.; Chang Y.; Morrissey D.V.; A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep 2018,22(9),2227-2235","journal-title":"Cell Rep"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"Gillmore J.D.","year":"2021","unstructured":"Gillmore J.D.; Gane E.; Taubel J.; Kao J.; Fontana M.; Maitland M.L.; Seitzer J.; O\u2019Connell D.; Walsh K.R.; Wood K.; Phillips J.; Xu Y.; Amaral A.; Boyd A.P.; Cehelsky J.E.; McKee M.D.; Schiermeier A.; Harari O.; Murphy A.; Kyratsous C.A.; Zambrowicz B.; Soltys R.; Gutstein D.E.; Leonard J.; Sepp-Lorenzino L.; Lebwohl D.; CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 2021,385(6),493-502","journal-title":"N Engl J Med"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666221108094736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/210721\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X21666221108094736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T04:29:12Z","timestamp":1693715352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/210721\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x21666221108094736","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}